Purple Biotech - PPBT Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 1,387.60%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.61
▲ +0.03 (5.22%)

This chart shows the closing price for PPBT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Purple Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PPBT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PPBT

Analyst Price Target is $9.00
▲ +1,387.60% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Purple Biotech in the last 3 months. The average price target is $9.00, with a high forecast of $10.00 and a low forecast of $8.00. The average price target represents a 1,387.60% upside from the last price of $0.61.

This chart shows the closing price for PPBT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Purple Biotech. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/20/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/18/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/16/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/15/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/14/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/13/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
4/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
3/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
2/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00Low
11/21/2023HC WainwrightBoost TargetBuy ➝ Buy$9.00 ➝ $10.00Low
8/30/2023HC WainwrightBoost TargetBuy ➝ Buy$7.00 ➝ $9.00Low
8/17/2023Chardan CapitalReiterated RatingBuyLow
7/21/2023JonestradingInitiated CoverageBuy$8.00Low
7/10/2023Chardan CapitalReiterated RatingBuyLow
2/9/2023Chardan CapitalReiterated RatingBuy$11.00Low
2/9/2023HC WainwrightReiterated RatingBuy$7.00Low
10/17/2022HC WainwrightInitiated CoverageBuy$7.00Low
9/8/2022Chardan CapitalInitiated CoverageBuy$11.00Low
12/31/2020HC WainwrightReiterated RatingBuy$25.00N/A
(Data available from 6/13/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/16/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
12/16/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/15/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
2/14/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/15/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/14/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/14/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/13/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Purple Biotech logo
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
Read More

Today's Range

Now: $0.61
Low: $0.58
High: $0.63

50 Day Range

MA: $0.59
Low: $0.40
High: $0.86

52 Week Range

Now: $0.61
Low: $0.30
High: $1.80

Volume

46,204 shs

Average Volume

146,920 shs

Market Capitalization

$15.27 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Purple Biotech?

The following Wall Street sell-side analysts have issued reports on Purple Biotech in the last twelve months: Chardan Capital, HC Wainwright, and Jonestrading.
View the latest analyst ratings for PPBT.

What is the current price target for Purple Biotech?

2 Wall Street analysts have set twelve-month price targets for Purple Biotech in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 1,387.6%. HC Wainwright has the highest price target set, predicting PPBT will reach $10.00 in the next twelve months. Jonestrading has the lowest price target set, forecasting a price of $8.00 for Purple Biotech in the next year.
View the latest price targets for PPBT.

What is the current consensus analyst rating for Purple Biotech?

Purple Biotech currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PPBT will outperform the market and that investors should add to their positions of Purple Biotech.
View the latest ratings for PPBT.

What other companies compete with Purple Biotech?

How do I contact Purple Biotech's investor relations team?

Purple Biotech's physical mailing address is ONE AZRIELI CENTER ROUND TOWER 132 MENACHEM BEGIN ROAD, TEL AVIV L3, 6701101. The company's listed phone number is (723) 933-3121 and its investor relations email address is [email protected]. The official website for Purple Biotech is www.kitovpharma.com. Learn More about contacing Purple Biotech investor relations.